Article ID Journal Published Year Pages File Type
6201125 Ophthalmology 2014 7 Pages PDF
Abstract
Short-term, high-dose chlorambucil therapy provides sustained periods of drug-free remission. With median follow-up of more than 8 years (mean, 11.6 years; range, 4-37 years), there was a low rate of recurrence and minimal long-term serious health consequences or adverse events. Because SO may be a lifelong condition and because chlorambucil therapy may offer long-term, drug-free remission, this treatment may be worth considering early in the decision-making process for severe sight-threatening disease.
Related Topics
Health Sciences Medicine and Dentistry Ophthalmology
Authors
, , , , , , , ,